1. Long-term prevalence of PTSD symptom in family members of severe COVID-19 patients: a serial follow-up study extending to 18 months after ICU discharge.
- Author
-
Nosaka N, Noguchi A, Takeuchi T, and Wakabayashi K
- Abstract
Background: Experiencing a loved one's stay in the intensive care unit (ICU) can profoundly affect families, often leading to post-intensive care syndrome-family (PICS-F), a condition particularly exacerbated during the COVID-19 pandemic. While PICS-F significantly impacts the mental health of families of ICU patients, especially in the context of COVID-19, the long-term effects beyond 12 months remain understudied. This study aims to explore the prevalence of PTSD-related symptoms and health-related quality of life (HRQOL) in family members up to 18 months after ICU discharge., Methods: This prospective study, conducted in a tertiary university hospital in Tokyo, enrolled family members of severe COVID-19 ICU patients (July 2020 to June 2022 with final follow-up ending in December 2023). The primary outcome was family member symptoms of PTSD at 6, 12 and 18 months after ICU discharge, measured by the Impact of Events Scale-Revised (presence of PTSD symptoms defined by score > 24). Secondary outcomes were family member symptoms of anxiety and depression, sleep disorders, and health-related quality of life (HRQOL) at the same timepoint., Results: Among 97 enrolled family members, 68 participated. At least one PTSD-related symptom was reported by 26% of family members, persisting over 18 months post-discharge (16% at 6 months, 23% at 12 months, and 25% at 18 months). A subgroup (15%) exhibited delayed-onset PTSD symptoms. Family members with PTSD-related symptoms reported lower HRQOL, especially in mental and social components., Conclusions: The study underscores the importance of long-term support for family members post-ICU discharge, given the sustained prevalence of PTSD-related symptoms among family members of severe COVID-19 patients., Competing Interests: Declarations. Ethics approval and consent to participate: This study was approved by the Tokyo Medical and Dental University Review Board (M2021-334). Written informed consent was obtained from all the family participants who responded to the initial survey questionnaire. For the corresponding patient information, the requirement for written informed consent was waived (opt-out) by the Institutional Review Board due to the retrospective study design. Consent for publication: Not applicable. Competing interests: Nobuyuki Nosaka received a research grant from Sharp Corporation, Osaka, Japan, for this study., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF